Published in Am J Psychiatry on October 01, 1994
A review of MRI findings in schizophrenia. Schizophr Res (2001) 8.95
MRI anatomy of schizophrenia. Biol Psychiatry (1999) 2.79
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry (2003) 2.16
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 1.96
What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull (2008) 1.80
Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest (2007) 1.74
MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. Am J Psychiatry (2002) 1.72
Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder. Biol Psychiatry (2004) 1.66
Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms. BMC Psychiatry (2006) 1.59
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther (2003) 1.57
Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull (2009) 1.51
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev (2013) 1.40
Reduction of caudate nucleus volumes in neuroleptic-naïve female subjects with schizotypal personality disorder. Biol Psychiatry (2006) 1.36
Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry (2007) 1.33
The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull (2008) 1.30
Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry (2012) 1.29
Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophr Bull (2009) 1.26
Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry (2001) 1.23
Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biol Psychiatry (2008) 1.16
Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"? Schizophr Bull (2008) 1.12
The brain in schizotypal personality disorder: a review of structural MRI and CT findings. Harv Rev Psychiatry (2001) 1.12
Volume deficits of subcortical nuclei in mood disorders A postmortem study. Eur Arch Psychiatry Clin Neurosci (2005) 1.10
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Res (2005) 1.07
Structural neuroimaging of the basal ganglia in schizophrenic patients: a review. Wien Med Wochenschr (2008) 1.04
Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm (Vienna) (2005) 1.02
Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J Neurosci (2012) 1.02
Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study. Am J Psychiatry (2007) 1.01
Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of illness. Schizophr Bull (2008) 0.99
Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci (2010) 0.95
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. Psychiatry Res (2012) 0.94
Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophr Bull (2010) 0.94
Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen. Schizophr Res (2009) 0.94
Understanding structural brain changes in schizophrenia. Dialogues Clin Neurosci (2006) 0.93
Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Front Psychiatry (2012) 0.93
A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. Psychopharmacology (Berl) (2009) 0.93
Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study. Neuroimage (2009) 0.93
Neuroimaging correlates of aggression in schizophrenia: an update. Curr Opin Psychiatry (2011) 0.92
Three-dimensional mapping of the lateral ventricles in autism. Psychiatry Res (2008) 0.91
Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin Neurosci (2013) 0.90
The neural correlates of implicit sequence learning in schizophrenia. Neuropsychology (2007) 0.90
Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia. Schizophr Res (2009) 0.89
MRI abnormalities of the hippocampus and cavum septi pellucidi in females with schizotypal personality disorder. Schizophr Res (2006) 0.89
A voxel-based morphometry comparison of regional gray matter between fragile X syndrome and autism. Psychiatry Res (2009) 0.89
Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr Res (2010) 0.89
Untreated illness duration correlates with gray matter loss in first-episode psychoses. Neuroreport (2009) 0.88
A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder. Curr Psychiatry Rep (2012) 0.88
Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse (2009) 0.87
Shape abnormalities of caudate nucleus in schizotypal personality disorder. Schizophr Res (2009) 0.87
Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci (2005) 0.87
The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanisms of neurotoxicity in first-episode psychosis. Can J Psychiatry (2014) 0.86
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. J Neuropsychiatry Clin Neurosci (2006) 0.85
Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem (2013) 0.84
Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry. Eur Arch Psychiatry Clin Neurosci (2010) 0.84
Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res (2013) 0.84
Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response. Synapse (2011) 0.83
Spontaneous parkinsonisms and striatal impairment in neuroleptic free youth at ultrahigh risk for psychosis. NPJ Schizophr (2015) 0.83
Effect of dopamine transporter genotype on caudate volume in childhood ADHD and controls. Am J Med Genet B Neuropsychiatr Genet (2010) 0.82
123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) (2004) 0.82
Shape of the basal ganglia in preadolescent children is associated with cognitive performance. Neuroimage (2014) 0.81
Neuroanatomical phenotypes in a mouse model of the 22q11.2 microdeletion. Mol Psychiatry (2013) 0.81
Subcortical correlates of individual differences in aptitude. PLoS One (2014) 0.80
A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PLoS One (2014) 0.80
Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review. Curr Neuropharmacol (2015) 0.79
Basal ganglia volumetric studies in affective disorder: what did we learn in the last 15 years? J Neural Transm (Vienna) (2005) 0.79
Size and shape of the caudate nucleus in individuals with bipolar affective disorder. Aust N Z J Psychiatry (2012) 0.79
Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study. Schizophr Bull (2015) 0.79
Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. Eur Arch Psychiatry Clin Neurosci (2009) 0.79
Larger brains in medication naive high-functioning subjects with pervasive developmental disorder. J Autism Dev Disord (2004) 0.78
Evidence for frontal-subcortical circuit abnormalities in bipolar affective disorder. Psychiatry (Edgmont) (2005) 0.78
Neuroimaging of schizophrenia: structural abnormalities and pathophysiological implications. Neuropsychiatr Dis Treat (2005) 0.78
Subcortical neuromorphometry in schizophrenia spectrum and bipolar disorders. Neuroimage Clin (2016) 0.78
Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder. Schizophr Res (2012) 0.77
Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment. CNS Spectr (2015) 0.77
First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2015) 0.76
A systematic examination of brain volumetric abnormalities in recent-onset schizophrenia using voxel-based, surface-based and region-of-interest-based morphometric analyses. J Negat Results Biomed (2015) 0.76
Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study. Sci Rep (2016) 0.75
Neural models of schizophrenia. Dialogues Clin Neurosci (2000) 0.75
Biclustered Independent Component Analysis for Complex Biomarker and Subtype Identification from Structural Magnetic Resonance Images in Schizophrenia. Front Psychiatry (2017) 0.75
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Fabrication of microfluidic systems in poly(dimethylsiloxane). Electrophoresis (2000) 9.45
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev (1998) 5.14
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell (1998) 4.77
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med (1993) 3.76
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry (2005) 3.74
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (1999) 3.48
A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem (2000) 3.26
Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation (1996) 2.98
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry (2000) 2.93
Fabrication of topologically complex three-dimensional microfluidic systems in PDMS by rapid prototyping. Anal Chem (2000) 2.81
Structural basis for self-association and receptor recognition of human TRAF2. Nature (1999) 2.74
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol (2000) 2.67
Catching up on schizophrenia: natural history and neurobiology. Neuron (2000) 2.63
Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry (1992) 2.59
Abnormalities of the septum pellucidum on MR scans in first-episode schizophrenic patients. AJNR Am J Neuroradiol (1992) 2.58
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord (1999) 2.46
Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 2.43
Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A (1997) 2.37
A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J Cell Biol (1995) 2.30
Binding of peptides with basic residues to membranes containing acidic phospholipids. Biophys J (1991) 2.30
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry (2005) 2.29
The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell (1999) 2.25
In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol (1998) 2.23
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 2.19
Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Arch Pathol Lab Med (1998) 2.11
Early postnatal development of corpus callosum and corticospinal white matter assessed with quantitative tractography. AJNR Am J Neuroradiol (2007) 2.11
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry (1999) 2.06
Trisomy eight in ES cells is a common potential problem in gene targeting and interferes with germ line transmission. Dev Dyn (1997) 2.05
[Sadistic fetishism--deadly passion. Forensic psychiatric assessment of sex offenders]. Nervenarzt (2008) 2.02
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull (1999) 1.99
Women are at greater risk than men for malpositioning of the endotracheal tube after emergent intubation. Crit Care Med (1994) 1.98
Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry (2000) 1.98
Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv (2001) 1.93
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
Unrelated agranulocytosis in a patient taking clozapine. J Clin Psychopharmacol (1993) 1.92
Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis (2010) 1.92
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol (1998) 1.91
Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci (1999) 1.90
PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol (2001) 1.86
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry (1997) 1.86
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry (2001) 1.86
TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci (2001) 1.76
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry (2012) 1.73
High-cooperativity coupling of electron-spin ensembles to superconducting cavities. Phys Rev Lett (2010) 1.69
Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem (2001) 1.66
Detection of mecA, femA, and femB genes in clinical strains of staphylococci using polymerase chain reaction. Epidemiol Infect (1994) 1.64
Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci U S A (2000) 1.64
Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry (1999) 1.61
Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer (2004) 1.61
Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) (1987) 1.60
The Structured Interview for Schizotypy (SIS): a preliminary report. Schizophr Bull (1989) 1.59
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene (2006) 1.59
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene (2010) 1.58
Morphology of single olivocerebellar axons labeled with biotinylated dextran amine in the rat. J Comp Neurol (1999) 1.57
Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A (1997) 1.57
Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci U S A (1995) 1.56
Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience (2007) 1.56
Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health (2003) 1.55
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia (2012) 1.55
Valproic acid therapy in childhood epilepsy. JAMA (1980) 1.54
Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry (1993) 1.54
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res (1990) 1.54
Mesohepatectomy for centrally located liver tumours. Br J Surg (2013) 1.53
Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol (1996) 1.53
Morphometric studies of the entorhinal cortex in neuropsychiatric patients and controls: clusters of heterotopically displaced lamina II neurons are not indicative of schizophrenia. Schizophr Res (1998) 1.53
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol (2000) 1.51
Phase-sensitive optical time-domain reflectometry with Brillouin amplification. Opt Lett (2014) 1.51
Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature (2001) 1.51
Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet (1991) 1.50
Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem (2001) 1.48
Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res (2001) 1.47
The role of lipoprotein processing by signal peptidase II in the Gram-positive eubacterium bacillus subtilis. Signal peptidase II is required for the efficient secretion of alpha-amylase, a non-lipoprotein. J Biol Chem (1999) 1.45
Miz1, a novel zinc finger transcription factor that interacts with Msx2 and enhances its affinity for DNA. Mech Dev (1997) 1.45
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res (2000) 1.44
Boron neutron capture enhancement of 252Cf brachytherapy. Int J Radiat Oncol Biol Phys (1990) 1.44
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry (2009) 1.44
D-Alanine substitution of teichoic acids as a modulator of protein folding and stability at the cytoplasmic membrane/cell wall interface of Bacillus subtilis. J Biol Chem (2000) 1.44
Three-dimensional fast low-angle shot imaging and computerized volume measurement of the hippocampus in patients with chronic epilepsy of the temporal lobe. AJNR Am J Neuroradiol (1991) 1.43